Composing codas to cervical cancer screening through an integrated crispr and fluorescent nucleic acid approach

Active Cooperative Agreement Awarded Last action

Award ID
U01CA279858
Recipient
Awarding agency
Obligated
$3,083,122

Award facts

Assistance listing
93.394 Cancer Detection and Diagnosis Research
Completion date 66% complete
Place of performance
Charlestown, MA 02129, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Challenges. Despite being curable when caught early, cervical cancer remains the second leading cause of death in women living in sub-saharan africa. Even with available screening technologies (cytology, visual inspection with acetic acid (via), and sometimes high-risk human papillomavirus [hrhpv] testing), only 10-20% of eligible women in low-and-middle-income countries (lmic) are currently screened. Barriers cited include technical expertise, laboratory capacity, cost, and access. Most developed countries have adopted PCR-based HPV screening, furthering the resource divide with lmics, where 80% of cancer deaths occur. Innovation. In dire response to the diagnostic gaps unveiled by the pandemic, team members within our group developed and validated in human specimens a robust and frugal technology to detect nucleic acid targets. The approach, crispr optical detection of anisotropy or coda, combines crispr/CAS (a nobel prize- winning technology for highly precise gene editing) with uorescence anisotropy (differential rotational motion of uorescent molecules). Automated nucleic acid readouts are generated in < 30 minutes. We have adopted this technology for: a) the detection of DNA and RNA markers of CIN2+; and b) reliable use by clinicians and clinical lab personnel in point-of-care settings. Our plan for this proposal is to operationalize this technology for low resource settings, notably our partner sites in uganda and ghana, with close lmic input. We will then leverage coda and other parameters to create a panel of tests to optimally detect CIN2+ in a single encounter. Aim 1: construct a robust coda platform for comprehensive HPV screening. Aim 2: further examine coda performance on human specimens and rene for lmic operations. Aim 3: develop a novel and rapid multi-modal algorithm for screen and treat in lmics. Impact. Given coda's core strengths in nucleic acid analyses (e.g., DNA or RNA), we envision an approach that yields fully quantitive readouts of high-risk HPV DNA and E6, E7, and P16 mrna. Since the coda assay underlies all readouts driving this proposal, a high potential exists for end-user-friendly, practical, and rapid triage of high-risk cervical disease or invasive cancer. These benets could help decentralize and harmonize screening efforts with those guidelines currently endorsed by resource-rich countries.

Transactions

Action Obligated Date
Amendment $126,580
Amendment $124,465
Amendment $161,039
Amendment $0
Amendment $0
Amendment $126,580
Amendment $126,580
Amendment $124,429
Amendment $124,429
Amendment $269,601
Amendment $269,601
Amendment $0
Amendment $527,535
Amendment $527,535
Original award $574,748
Show all 15

Subawards

Subrecipient Amount Awarded
Mbarara University Of Science And Technology The Main goal of this research is to develop and validate novel diagnostic technologies for use in cervical cancer screening at the point of care in low… $126,580
Kwame Nkrumah University Of Science And Technology The Main goal of this research is to develop and validate novel diagnostic technologies for use in cervical cancer screening at the point of care in low… $124,429
Kwame Nkrumah University Of Science And Technology The main goal of this research is to develop and validate novel diagnostic technologies for use in cervical cancer screening at the point of care in… $124,197
Mbarara University Of Science And Technology The main goal of this research is to develop and validate novel diagnostic technologies for use in cervical cancer screening at the screening at the point of… $142,250

Quick answers

Who received award U01CA279858?

U01CA279858 was awarded to The General Hospital Corporation by National Cancer Institute (National Institutes of Health) on July 1, 2023.

How much is award U01CA279858 worth?

$3,083,122 has been obligated on U01CA279858.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login